Outcomes in B non-Hodgkin lymphoma (B-NHL) patients undergonig autologous stem cell transplant (ASCT) in the Rituximab era: risk of hypogammaglobulinaemia and impact on post-ASCT infections

被引：0
|
作者：
Sola Soto, M. [1 ]
Serna Munoz, M. J. [1 ]
Munoz Ballester, J. [1 ]
Lopez Matencio, P. Iniesta [1 ]
Sanchez Blanco, J. J. [1 ]
Castilla Llorente, C. [1 ]
De Arriba de La Fuente, F. [1 ]
Garcia Malo, M. D. [1 ]
Perez Ceballos, E. [1 ]
Lopez Godino, O. [1 ]
Heras, I. [1 ]
Vicente Garcia, V. [1 ]
机构：
[1] Hosp Morales Meseguer, Hematol, Murcia, Spain
来源：
BONE MARROW TRANSPLANTATION | 2016年 / 51卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P727
引用
收藏
页码：S502 / S503
页数：2
相关论文
共 50 条
  • [31] Autologous stem cell transplantation (ASCT) for elderly patients (≥ 60 years) with non-hodgkin's lymphoma (NHL):: An analysis based on EBMT registry.
    Jantunen, Esa
    Canals, Carmen
    Blaise, Didier
    Rambaldi, Alessandro
    Tilly, Herve
    Conde, Eulogio
    Gisselbrecht, Christian
    Dreger, Peter
    Ossenkoppele, G. J.
    Allione, Bernardino
    Pfreudschuh, M.
    Craddock, Charles
    Sureda, Anna
    BLOOD, 2007, 110 (11) : 559A - 559A
  • [32] Phase I study of bendamustine combined with rituximab in relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL)
    Taniwaki, M.
    Ogura, M.
    Matsumoto, Y.
    Uchida, T.
    Ohmachi, K.
    Ando, K.
    Watanabe, T.
    Tobinai, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [33] Outcome of Relapse in Children/Adolescents with B-Cell Non-Hodgkin Lymphoma (B-NHL) and Mature Acute Leukemia (B-AL) Treated in the Rituximab (R) Era
    Rigaud, C.
    Auperin, A.
    Jourdain, A.
    Schmitt, C.
    Paillard, C.
    Couec, M. L.
    Aladjidi, N.
    Gandemer, V.
    Lambilliote, A.
    Plat, G.
    Michon, J.
    Leblanc, T.
    Patte, C.
    Minard-Colin, V.
    PEDIATRIC BLOOD & CANCER, 2016, 63 : S36 - S36
  • [34] Phase II study of oral Fludarabine (FAMP) in combination with rituximab in indolent B-cell non-hodgkin lymphoma (B-NHL)
    Ishizawa, Kenichi
    Tobinai, Kensei
    Ogura, Michinori
    Itoh, Kuniaki
    Aorishima, Yasuo
    Ando, Kiyoshi
    Yamamoto, Joji
    Watanabe, Takashi
    Uchida, Toshiki
    Nakata, Masanobu
    Hayashi, Masaki
    Hotta, Tomomitsu
    BLOOD, 2007, 110 (11) : 387A - 387A
  • [35] Evaluation of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) in patients with non-Hodgkin's lymphoma (NHL) having previously received autologous stem cell transplant (ASCT)
    Jacobs, SA
    McCook, B
    Torok, F
    Avril, N
    Vidnovic, N
    Joyce, J
    Molina, A
    BLOOD, 2004, 104 (11) : 395B - 395B
  • [36] High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era
    Ban-Hoefen, Makiko
    Kelly, Jennifer L.
    Bernstein, Steven H.
    Liesveld, Jane
    Constine, Louis
    Becker, Michael
    Milner, Laurie
    Phillips, Gordon
    Friedberg, Jonathan W.
    LEUKEMIA & LYMPHOMA, 2012, 53 (05) : 830 - 835
  • [37] TANDEM AUTOLOGOUS ALLOGENEIC STEM CELL TRANSPLANTATION IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED/REFRACTORY MATURE B-CELL NON-HODGKIN LYMPHOMA (B-NHL)
    Gardenswartz, A.
    Mehta, B.
    El-Mallawany, N.
    van de Ven, C.
    Hochberg, J.
    Flower, A.
    Morris, E.
    Harrison, L.
    Basso, J.
    Gerard, P.
    Ayello, J.
    Baxter-Lowe, L. A.
    Cairo, M. S.
    PEDIATRIC BLOOD & CANCER, 2019, 66
  • [38] Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma
    Wildes, Tanya M.
    Augustin, Kristan M.
    Sempek, Diane
    Zhang, Qin Jean
    Vij, Ravi
    Dipersio, John F.
    Devine, Steven M.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (07) : 840 - 846
  • [39] Dose finding trial of Yttrium 90 ibritumomab tiuxetan (90YIT) with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
    Flinn, I. W.
    Kahl, B. S.
    Frey, E. C.
    Bianco, J. A.
    Hammes, R. J.
    Webb, J.
    Swinnen, L. J.
    Sgouros, G.
    Wahl, R. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 430S - 430S
  • [40] Dose finding trial of yttrium 90 (90Y) ibriturnomab tiuxetan with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
    Flinn, IW
    Kahl, BS
    Frey, E
    Bianco, JA
    Hammes, RJI
    Billing, LS
    Swinnen, LJ
    Sgouros, G
    Wahl, RL
    BLOOD, 2004, 104 (11) : 256A - 256A
12345